Filter
45
Filtered Results: 45
Text search:
Covishield
Featured
Recommendations
10
Language
Document type
Guidelines
19
Fact sheets
10
Manuals
6
Studies & Reports
6
Situation Updates
2
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
Argentina
12
Brazil
4
India
3
Latin America and the Carribbean
2
Ukraine
1
Syria
1
West and Central Africa
1
East and Southern Africa
1
South Sudan
1
Ecuador
1
Authors & Publishers
Publication Years
Category
COVID-19
24
Guidelines
8
Studies & Reports
3
Vaccine-preventable Diseases
2
Women & Child Health
2
Information, Education and Communication (IEC)
1
Statistics
1
Toolboxes
Country specific documents
17
Vaxzevria (Astra Zeneca)
12
Access & Strategy
5
Immunization Guidelines
5
Infection Control General
3
Educational Settings
3
Workplace
3
Physical Distancing
3
Context & Facts, Travel Advice
2
Moderna
2
Biontech/Pfizer Comirnaty
2
Booster Doses
2
Vaccination
1
Clinical Guidelines
1
Situation Reports & Updates
1
Prevention & Preparedness
1
COVID-19
1
For Pregnant Women
1
Country-specific Platforms
1
Vaccination & Strategy
1
Non-pharmaceutical interventions (NPIs)
1
Dashboards & Resource Platforms
1
Fair Allocation & Ethical Aspects
1
SARS-CoV-2 Variants
1
COVAX Initiative
1
Sputnik V
1
Research & Pipeline
1
Inactivated COVID-19 Vaccines
1
Guidelines & Manuals
1
General
1
Situation Reports & Updates
1
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...
7 April 2021
Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.
Available in Englisch, French and Russian
This situation update is on the Novel Coronavirus (COVID-19) reported cases and deaths, Globally, Regionally, for Barbados and the Eastern Caribbean Countries, French Territories, and the United Kingdom Overseas Territories.
Position paper on vaccination with Sputnik V vaccine | National Commission on Vaccine Safety (CoNaSeVa) | 12 May 2021
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel
Emergency medical teams (EMTs) play an important role in strengthening health service networks in terms of their strategies and tactics for planning mass vaccination programs, especially in remote or under-resourced areas or those overwhelmed by COVID-19. EMTs experience deploying in remote areas an...
